Home Magazines Editors-in-Chief FAQs Contact Us

Thrombolytics still the first therapeutic weapon against acute ST-segment elevation myocardial infarction

Journal of Cardiology & Current Research
Fernando Leonel Benaim, Sebastian Fonseca, Hernan Cohen Arazzi, Mailen Blanco

PDF Full Text


Cardiovascular disease (CVD) is the leading cause of death worldwide, being coronary events the most common cause of CVD. In the case of an acute ST-segment elevation myocardial infarction, the conventional treatment involves the reperfusion of the culprit artery as soon as possible as angioplasty has replaced the thrombolysis therapy. We present two patients with acute ST-segment elevation myocardial infarction. The first patient showed an ST-segment elevation of the anterolateral wall, and the second one, in the inferolateral wall. In both cases we performed rapid reperfusion with thrombolytics (ischemic time less than 30minutes), with good response. The first patient showed a lesion in the subendocardial myocardium in the late gadolinium enhancement in cardiovascular magnetic resonance imaging. Taking into account the time delays of patients-derivation and door-to-balloon time in Argentina, these cases reinforce the indication of thrombolytics as the treatment of choice.


acute myocardial infarction, culprit artery, thrombolytics, early reperfusion strategy, cardiac magnetic resonance, CVD, cardiovascular disease, STEMI, ST-segment elevation myocardial infarction, AMI, acute myocardial infarction, RCA, right coronary artery, CA, circumflex artery, DA, descending artery, LV, lateral-ventricular, IT, ischemic time